[HTML][HTML] Targeted intestinal delivery of incretin secretagogues—towards new diabetes and obesity therapies
FM Gribble, CL Meek, F Reimann - Peptides, 2018 - Elsevier
A new strategy under development for the treatment of type 2 diabetes and obesity is to
mimic some of the effects of bariatric surgery by delivering food-related stimuli to the distal
gastrointestinal tract where they should enhance the release of gut hormones such as
glucagon-like peptide-1 (GLP-1) and peptideYY (PYY). Methods include inhibition of food
digestion and absorption in the upper GI tract, or oral delivery of stimuli in capsules or
pelleted form to protect them against gastric degradation. A variety of agents have been …
mimic some of the effects of bariatric surgery by delivering food-related stimuli to the distal
gastrointestinal tract where they should enhance the release of gut hormones such as
glucagon-like peptide-1 (GLP-1) and peptideYY (PYY). Methods include inhibition of food
digestion and absorption in the upper GI tract, or oral delivery of stimuli in capsules or
pelleted form to protect them against gastric degradation. A variety of agents have been …